Menu ×

HEALTHCARE & PHARMACEUTICALDISCOUNT VALID TILL 31st-JANUARY , 2022

Motor Neuron Disease Treatment Market Segmentation by Drug Class (Riluzole, and Edaravone); and by End User (Multidisciplinary Clinics, Hospitals, Social Work Facilities, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Motor Neuron Disease Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • June 2021- Mitsubishi Tanabe Pharma America, Inc. announced that EXSERVAN, which is the first oral film formulation of riluzole is now available in the United States to treat amyotrophic lateral sclerosis (ALS).

  • November 2019- Aquestive Therapeutics granted a development and commercialization license to Zambon Pharma for its investigational oral formulation of riluzole as a treatment for ALS in the European Union.

Global Motor Neuron Disease Treatment Market Highlights 2022 – 2030

The global motor neuron disease treatment market is estimated to garner a sizeable revenue and grow at a notable CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing incidences of chronic diseases around the globe, and growing levels of awareness about motor neuron diseases. The global average incidence rate of amyotrophic lateral sclerosis (ALS), which is a motor neuron disorder, is about 1 in 50,000 people per year, i.e., approximately 5,500 to 6,500 new diagnoses every year. Along with these, rising technological advancements in medical science, especially in developed and developing nations is also expected to drive market growth in the forthcoming years. Furthermore, continued environmental exposure to toxins in workplace and home, and high consumption of narcotic substances are also crucial factors that trigger motor neuron diseases in people. This in turn is projected to offer ample growth opportunities in the near future.

Motor Neuron Disease Treatment Market Graph

The market is segmented by end user into multidisciplinary clinics, hospitals, social work facilities, and others, out of which, the hospitals segment is anticipated to hold the largest share in the global motor neuron disease treatment market. This can be accounted to the high emphasis of patients with neurological disorders to get treatment by a medical professional in a hospital facility. Apart from this, increasing number of admissions in hospitals is also predicted to boost the growth of the market segment in the years to come. Additionally, on the basis of drug class, the riluzole segment is assessed to acquire the largest share during the forecast period owing to the ability of the drug to slow down worsening of motor neuron disease and prolong survival by 6-19 months.CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Motor Neuron Disease Treatment Market Regional Synopsis

On the basis of geographical analysis, the global motor neuron disease treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of large patient pool, and increasing government support to boost the healthcare infrastructure in the region. As per the data provided by the World Bank, there were an average of 4.31 hospital beds per 1000 people in China in 2017, up from 4.02 beds in 2016. Moreover, the market in North America is expected to grab the largest share during the forecast period, which can be credited to the high healthcare expenditure, and availability of reimbursement coverage by healthcare providers. In addition, strong presence of prominent market players is also anticipated to bolster the market growth in the region in the upcoming years.

Motor Neuron Disease Treatment Market Share Image

The global motor neuron disease treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global motor neuron disease treatment market includes the following segments:

By Drug Class

  • Riluzole
  • Edaravone

By End User

  • Multidisciplinary Clinics
  • Hospitals
  • Social Work Facilities
  • Others

Growth Drivers

  • Increasing Incidences of Chronic Diseases Globally
  • Growing Levels of Awareness about Motor Neuron Diseases

Challenges

  • Lack of Skilled Medical Professionals in Lower Economic Regions

Top Featured Companies Dominating the Market

  • European Technologies Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Conscientia Industrial Co., Ltd
  • CSNpharm, Inc.
  • Aozeal Certified Standards (AOCS), Inc.
  • Finetech Industry Limited
  • Skyrun Industrial Co., Ltd.
  • Santa Cruz Biotechnology, Inc.
  • Amadis Chemical Company Limited
  • Mitsubishi Tanabe America, Inc.
  • Aquesituve Therapeutics

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved